The rise of theranostics: Part 4 -- Women's theranostics on the horizon
AuntMinnie
JULY 8, 2024
With CAM-H2, we engineered the protein to bind to a different epitope on HER2 to other approved therapies, so the option of combining CAM-H2 with other therapies is definitely an opportunity." In addition, the mean tissue dose did not reach the maximum tolerated dose for kidney, bone marrow, or liver.
Let's personalize your content